|
|
Volumn 9, Issue 3, 2005, Pages 214-217
|
|
Depo-Provera: new concerns--same issues?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CONTRACEPTIVE AGENT;
MEDROXYPROGESTERONE ACETATE;
ADOLESCENT;
ADULT;
AGE;
ARTICLE;
BONE DENSITY;
CANADA;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
DRUG EFFECT;
DRUG LABELING;
FEMALE;
FEMALE INFERTILITY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
INFORMED CONSENT;
OSTEOPOROSIS;
PATIENT EDUCATION;
PATIENT SELECTION;
RISK ASSESSMENT;
RISK FACTOR;
TIME;
UNITED STATES;
WOMEN'S HEALTH;
ADOLESCENT;
ADULT;
AGE FACTORS;
BONE DENSITY;
CANADA;
CLINICAL TRIALS;
CONTRACEPTIVE AGENTS, FEMALE;
DRUG LABELING;
FEMALE;
HUMANS;
INFERTILITY, FEMALE;
INFORMED CONSENT;
MEDROXYPROGESTERONE 17-ACETATE;
OSTEOPOROSIS;
PATIENT EDUCATION;
PATIENT SELECTION;
RISK ASSESSMENT;
RISK FACTORS;
TIME FACTORS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
WOMEN'S HEALTH;
|
|
EID: 25144472268
PISSN: 10915923
EISSN: None
Source Type: Journal
DOI: 10.1177/1091592305279118 Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
